Abstract
Mosaic loss of chromosome Y (mLOY) is the most commonly detected mosaic chromosomal alteration, and is associated with a range of health outcomes in males. We detected mLOY in 106,054 European (EUR), 13,927 admixed African (AFR), and 6,127 Hispanic (HIS) participants of the Million Veteran Program (MVP; Ntotal=544,112). mLOY was positively associated with cigarette smoking, and negatively with obesity and type 2 diabetes. Multi-ancestry genome-wide association meta-analysis of MVP and UK Biobank mLOY summary statistics, jointly comprising 167,899 cases and 581,224 controls, identified 380 independent risk loci–240 of which were novel. GWAS in MVP high cell fraction (CF>10%) mLOY cases exhibited stronger effect sizes across risk loci. Local-ancestry-aware GWAS resolved ancestry-specific signals at BCL2L1 and SETBP1. Integrative eQTL analyses highlighted 51 genes that causally influence mLOY via differential expression. Finally, traits with genetic correlations and polygenic scores significantly associated with mLOY were selected for Mendelian randomization (MR), implicating thirteen traits as causal influences on mLOY, including triglycerides, high-density lipoprotein, and body mass index.
Competing Interest Statement
A.G.B. is on the scientific advisory board of TenSixteen Bio unrelated to the present work. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. D.K. is a scientific advisor and reports consulting fees from Bitterroot Bio, Inc unrelated to the present work. The other authors declare no competing interests.
Funding Statement
This study was funded by the Department of Veterans Affairs Office of Research & Development Million Veteran Program (MVP) award #000.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Central IRB of the VA Office of Research & Development gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵33 BridgeBio Pharma, Palo Alto, CA
↵‡ Saiju Pyarajan: saiju.pyarajan{at}va.gov
↵* Lists of authors and their affiliations appear at the end of the paper.
We have added several major analyses to this study. These include: (1) A meta-analysis of MVP mosaic loss of chromosome Y (mLOY) GWAS results with a previous GWAS performed in UK Biobank; this allowed us to identify 73 additional novel loci. (2) Novel high cell fraction (>10%) mLOY GWAS sensitivity analyses for MVP ancestries, which revealed that these advanced cases exhibited stronger effect sizes across risk loci. (3) Rigorous assessments of the effects of age and ancestry on mLOY prevalence, including sample weighting to achieve optimal covariate balance. (4) A prevalent disease PheWAS, which identified many associations between mLOY and comorbidities using the extensive electronic health records of MVP; this included type 2 diabetes, gout, and renal and heart diseases.
Data availability
The full summary level association data from the meta-analysis and individual population association analyses in MVP will be available via the dbGaP study accession number phs001672. Full transcriptome-wide association study results are available upon request.
